The treatment, a protein called interferon beta, has been developed by the UK biotech company Synairgen and a team of scientists at the University of Southampton.
Interferon beta, produced naturally by the body when it gets a viral infection, is inhaled directly into the lungs of patients with coronavirus using a nebuliser, with the aim of reducing viral load and stimulating an immune response.
Read the full article (NIHR Oxford Biomedical Research Centre website)